Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B

Young Kul Jung, Jong Eun Yeon, Woo Sik Han, Ji Hoon Kim, Jeong Han Kim, Jong Jae Park, Jae Seon Kim, Young-Tae Bak, Wangdon Yoo, Sun Pyo Hong, Soo Ok Kim, So Young Kwon, Kwan Soo Byun, Chang Hong Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log 10 copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.

Original languageEnglish
Pages (from-to)212-218
Number of pages7
JournalGut and Liver
Volume4
Issue number2
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Antiviral Agents
Hepatitis B virus
Therapeutics
DNA
Hepatitis B e Antigens
Mutation Rate
adefovir
Real-Time Polymerase Chain Reaction
Serum

Keywords

  • Adefovir dipivoxil
  • Drug resistance
  • Virologic response

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B. / Jung, Young Kul; Yeon, Jong Eun; Han, Woo Sik; Kim, Ji Hoon; Kim, Jeong Han; Park, Jong Jae; Kim, Jae Seon; Bak, Young-Tae; Yoo, Wangdon; Hong, Sun Pyo; Kim, Soo Ok; Kwon, So Young; Byun, Kwan Soo; Lee, Chang Hong.

In: Gut and Liver, Vol. 4, No. 2, 01.06.2010, p. 212-218.

Research output: Contribution to journalArticle

@article{27259a93b7364de886c576adab036672,
title = "Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B",
abstract = "Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log 10 copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54{\%}). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B {"}e{"} antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32{\%} and 14{\%} at 12 months treatment, respectively (p=0.018), and 40{\%} and 27{\%} at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0{\%} and 6{\%} at 12 months of treatment, respectively (p=0.033), and 21{\%} and 42{\%} at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0{\%} and 7{\%} at 12 months of treatment, respectively (p=0.072), and 9{\%} and 25{\%} at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.",
keywords = "Adefovir dipivoxil, Drug resistance, Virologic response",
author = "Jung, {Young Kul} and Yeon, {Jong Eun} and Han, {Woo Sik} and Kim, {Ji Hoon} and Kim, {Jeong Han} and Park, {Jong Jae} and Kim, {Jae Seon} and Young-Tae Bak and Wangdon Yoo and Hong, {Sun Pyo} and Kim, {Soo Ok} and Kwon, {So Young} and Byun, {Kwan Soo} and Lee, {Chang Hong}",
year = "2010",
month = "6",
day = "1",
doi = "10.5009/gnl.2010.4.2.212",
language = "English",
volume = "4",
pages = "212--218",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

TY - JOUR

T1 - Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated lamivudine-resistant chronic hepatitis B

AU - Jung, Young Kul

AU - Yeon, Jong Eun

AU - Han, Woo Sik

AU - Kim, Ji Hoon

AU - Kim, Jeong Han

AU - Park, Jong Jae

AU - Kim, Jae Seon

AU - Bak, Young-Tae

AU - Yoo, Wangdon

AU - Hong, Sun Pyo

AU - Kim, Soo Ok

AU - Kwon, So Young

AU - Byun, Kwan Soo

AU - Lee, Chang Hong

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log 10 copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.

AB - Background/Aims: The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B. Methods: Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log 10 copies/mL after 12 months of ADV treatment. Results: VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006). Conclusions: Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.

KW - Adefovir dipivoxil

KW - Drug resistance

KW - Virologic response

UR - http://www.scopus.com/inward/record.url?scp=77953553828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953553828&partnerID=8YFLogxK

U2 - 10.5009/gnl.2010.4.2.212

DO - 10.5009/gnl.2010.4.2.212

M3 - Article

C2 - 20559524

AN - SCOPUS:77953553828

VL - 4

SP - 212

EP - 218

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -